<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042908</url>
  </required_header>
  <id_info>
    <org_study_id>LBL-003-CN-001</org_study_id>
    <nct_id>NCT05042908</nct_id>
  </id_info>
  <brief_title>Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies</brief_title>
  <official_title>Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-003 Injection in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Leads Biolabs Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Leads Biolabs Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid&#xD;
      tumors .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase I clinical study evaluating LBL-003 monotherapy in patients with&#xD;
      advanced solid tumors in dose escalation. The overall design of the study is shown in the&#xD;
      figure below. The purpose of the LBL-003 single-dose escalation study in subjects with&#xD;
      advanced solid tumors is to evaluate the safety and tolerability of monotherapy to determine&#xD;
      the MTD (or MAD) and clinically recommended doses of LBL-003 monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjcects with adverse events and serious adverse events</measure>
    <time_frame>All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (30±7 days after drug withdrawal or before the start of new anti-tumor therapy) ]</time_frame>
    <description>The safety profile of LBL-003 will be assessed by monitoring the adverse event(AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE)v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>During the first two Cycles(each cycle is 14 days)</time_frame>
    <description>MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first two cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>During the first two Cycles(each cycle is 14 days)</time_frame>
    <description>DLT is defined as a toxicities(adverse event at least possibly related to LBL-003 )occurring during the DLT observation period(the initial 28 days).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: LBL-003Injection The test drugLBL-003will be preset with 6 escalation dose levels: dose A, dose B, dose C, dose D and dose E, dose F , administered twice a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBL-003Injection</intervention_name>
    <description>LBL-003 was given every two weeks for treatment</description>
    <arm_group_label>A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors</arm_group_label>
    <other_name>LBL-003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Both male and female aged Age ≥ 18 and ≤ 75;&#xD;
&#xD;
          2. ECOG score: 0-1;&#xD;
&#xD;
          3. The subjects voluntarily participate in the study, sign the Informed Consent Form,&#xD;
             with good compliance, and can cooperate with the follow-up.&#xD;
&#xD;
          4. Subjects with advanced malignant solid tumors confirmed by histology or cytology have&#xD;
             failed the standard treatment or have no standard treatment protocol or are not&#xD;
             suitable for standard treatment at this stage.&#xD;
&#xD;
          5. Subjects should have at least one evaluable lesion as defined by RECIST V1.1;Expected&#xD;
             survival period ≥ 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persons with known hypersensitivity to any of the active ingredients or excipients of&#xD;
             LBL-003 Injection or a history of atopic allergic reactions (asthma, rheumatism,&#xD;
             eczematous dermatitis) who, in the judgment of the investigator, are not suitable for&#xD;
             treatment with the test drug.&#xD;
&#xD;
          2. Subjects with active central nervous system metastases (regardless of whether they&#xD;
             have received treatment), including symptomatic brain metastases, meningeal&#xD;
             metastases, or spinal cord compression, but asymptomatic brain metastases (no&#xD;
             progression and/or at least 4 weeks after radiotherapy) No neurological symptoms or&#xD;
             signs after surgical resection, and dexamethasone or mannitol treatment is not&#xD;
             required);&#xD;
&#xD;
          3. Have received major surgery within 4 weeks before the first administration;&#xD;
&#xD;
          4. Subjects can not tolerate intravenous administration and have difficulty in venous&#xD;
             blood collection (if there is a history of fainting needles and bleeding);&#xD;
&#xD;
          5. Women during pregnancy or lactation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suxia Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lei liu</last_name>
    <phone>025-83378099-828</phone>
    <email>liulei@leadsbiolabs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Lv</last_name>
    <phone>025-83378099-829</phone>
    <email>lvting@leadsbiolabs.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>lei liu</last_name>
      <phone>025-83378099-828</phone>
      <email>liulei@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>ting lv</last_name>
      <phone>025-83378099-829</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>lei liu</last_name>
      <phone>025-83378099-828</phone>
      <email>liulei@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Lv</last_name>
      <phone>025-83378099-829</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shangdong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>lei liu</last_name>
      <phone>025-83378099-828</phone>
      <email>liulei@leadsbiolabs.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting lv</last_name>
      <phone>025-83378099-828</phone>
      <email>lvting@leadsbiolabs.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

